Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(145)
- Other Apoptosis(883)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC70298
Peginterferon beta-1a
Peginterferon β-1a是第一个聚乙二醇化的干扰素β -1a分子。
-
GC70289
AC-VEID-CHO TFA
AC-VEID-CHO TFA是一种肽衍生的caspase抑制剂,对caspase -6、caspase -3和caspase -7具有抑制作用,IC50值分别为16.2 nM、13.6 nM和162.1 nM。
-
GC70257
Gallium maltolate
Gallium maltolate(GAM)是一种具有抗癌和抗炎活性的细胞凋亡诱导剂。
-
GC70242
Thymocartin TFA
Thymocartin TFA是胸腺素的TFA盐形式。
-
GC91427
Glutaminase C Inhibitor 11
谷氨酰胺酶C抑制剂11是一种谷氨酰胺酶C(GAC)的抑制剂。它能够抑制GAC酶活性(EC50 = 10.64 nM),并降低A549非小细胞肺癌(NSCLC)细胞的存活率(IC50 = 4.025 nM)。
-
GC91403
HR68
PP21
HR68是一种抗癌药物,是过氧化物酶体增殖激活受体(PPAR)激动剂芬布拉酸的衍生物。它可以降低LN-229恶性胶质母细胞瘤细胞的存活率(IC50 = 1.17uM)。 -
GC91360
NM-3
NM-3是一种合成异香豆素,可以抑制血管生成。
-
GC26144
Menthol
Menthol 是个天然的止痛剂。Menthol 通过抑制神经元细胞膜的 Ca++ 电流,刺激冷感受器,从而产生凉的感觉。
-
GC91298
(±)-Linalool-d3
dl-Linalool-d3
一种用于量化(±)-芳樟醇的内部标准。
-
GC91297
Cholesterol-Doxorubicin
Chol-DOX
一种阿霉素的前药形式。
-
GC91228
SSE1806
一种微管不稳定剂
-
GC91208
Spiroxamine-d4
一种用于测量斯比洛克胺的内部标准
-
GC91176
AOH1996
一种PCNA抑制剂
-
GC91162
Glucosamine Cholesterol
一种基于葡萄糖胺的脂质共轭物
-
GC91154
33-BCRP Inhibitor
33-Breast Cancer Resistance Protein Inhibitor
一种BCRP抑制剂
-
GC91113
A011
一种ATM激酶抑制剂
-
GC91096
S-72
一种微管聚合抑制剂。
-
GC91088
AMX12006
一种EP4受体拮抗剂
-
GC91060
Ferritin PROTAC DeFer-2
Ferritin Proteolysis-targeting Chimera DeFer2
一种促进铁蛋白降解的PROTAC
-
GC91049
Iturin A-2
C14 Iturin
一种具有多种生物活性的环状脂肽
-
GC91040
AP-1
一种促进ALK降解的PROTAC
-
GC91028
L-K6L9 (trifluoroacetate salt)
一种细胞溶解肽(即能够破坏细胞的蛋白质分子)。
-
GC90889
5-(3'-Hydroxyphenyl)-γ-Valerolactone
δ-(3'-Hydroxyphenyl)-γ-Valerolactone, 5-(3'-Hydroxyphenyl)-γ-VL, δ-(3'-Hydroxyphenyl)-γ-VL, (3'-hydroxy)-PVL
多种多酚的代谢产物。
-
GC90886
SZM-1209
一种RIPK1抑制剂
-
GC90883
Purine riboside-5'-O-triphosphate (sodium salt)
PRTP, Purine Riboside Triphosphate, PTP, PuTP
一种星形菜碱的活性代谢物。
-
GC90659
6-epi COTC
一种具有抗癌活性的COTC衍生物。
-
GC90582
Perfluorooctanesulfonic Acid
Heptadecafluorooctanesulfonic Acid, Perfluorooctane sulfonate, Perfluorooctylsulfonic Acid, PFOS
一种全氟烷基物质
-
GC90549
5-Aminoimidazole-4-carboxamide (hydrate)
AIC
一种合成前体
-
GC90489
AC 187 (trifluoroacetate salt)
Acetyl-(Asn30,Tyr32)-Calcitonin8-32, Acetyl-Asn30,Tyr32Salmon Calcitonin (8 -37), Acetyl-Asn30,Tyr32 sCT(8 -37)
一种钙降素和淀粉样蛋白受体的拮抗剂。
-
GC90483
Magainin 1 (trifluoroacetate salt)
MG1
一种抗微生物阳离子肽。
-
GC90076
HA-14-1
一种Bcl-2抑制剂
-
GC70154
Yakuchinone A
Yakuchinone A 是一种可以从 Alpinia oxyphylla 果实分离得到的天然产物,可以诱导细胞凋亡 (apoptosis),具有抗癌、抗炎活性。
-
GC70145
WL12
WL12 是一种特异性靶向程序性死亡配体 1 (PD-L1) 结合肽。WL12 可以通过不同的放射性核素进行放射性标记,产生放射性示踪剂,评估肿瘤 PD-L1 的表达。
-
GC70137
Vudalimab
Vudalimab 是一种有效的 PD-1 和 CTLA-4 双重抑制剂,是一种完全人源化的双特异性单克隆抗体。Vudalimab 靶向免疫检查点受体 PD-1 和 CTLA-4,促进肿瘤选择性 T 细胞激活。
-
GC70114
Venetoclax-d8
ABT-199-d8; GDC-0199-d8; RG7601-d8
Venetoclax-d8 是 Venetoclax 氘代物。Venetoclax (ABT-199; GDC-0199) 是一种高效,有选择性和口服有效的 Bcl-2 抑制剂,Ki 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。
-
GC70104
Utomilumab
PF 05082566
Utomilumab (PF 05082566) 是一种人源化的 IgG2 mAb 激动剂,靶向T 细胞共刺激受体 4-1BB/CD137。Utomilumab 可用于复发/难治性滤泡性淋巴瘤 (FL) 和其他 CD20+ 非霍奇金淋巴瘤 (NHL) 的研究。 -
GC70039
TNF-α (46-65), human TFA
TNF-α (46-65), human (TFA) 是人 TNF-α 的多肽片段。
-
GC70026
Thymidine 3',5'-diphosphate tetrasodium
Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium
Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium 是葡萄球菌核酸酶和含有 1 的都铎结构域 (SND1,MicroRNA 调控复合体 RISC 亚基) 与 [3,5-2H2] 酪氨酸核酸酶 ( [3,5-2H2] tyrosyl nuclease) 的选择性抑制剂。Thymidine 3',5'-diphosphate tetrasodium 具有抗肿瘤活性,在生化反应也可用作催化剂。 -
GC69968
Sulanemadlin
ALRN-6924; MP-4897
Sulanemadlin是一种基于p53靶点的膜渗透性强效大环拟肽化合物,是一种稳定的α-螺旋肽。 -
GC69934
Spartalizumab
PDR001
Spartalizumab (PDR001) 是一种人源化的免疫球蛋白 4 单克隆抗体,以亚纳摩尔活性结合 PD-1,并阻断与 PD-L1 和 PD-L2 的相互作用。Spartalizumab 可用于甲状腺未分化癌 (ATC) 的研究。 -
GC69912
SLC7A11-IN-1
SLC7A11-IN-1 是一种有效的SLC7A11 抑制剂。SLC7A11-IN-1 显示出抗增殖活性。SLC7A11-IN-1 抑制细胞侵袭和转移。SLC7A11-IN-1 诱导细胞凋亡 (Apoptosis) 和细胞周期停滞在 S 期。SLC7A11-IN-1 具有抗肿瘤活性。
-
GC69899
SIRT6 activator 12q
SIRT6 activator 12q 是有效的、选择性的和具有口服活性的 SIRT6 激活剂,对 SIRT1、SIRT2、SIRT3、SIRT5、SIRT6 的 IC50 值分别为 171.20、>200、>200、>200、0.58 μM。SIRT6 activator 12q 抑制细胞生长和迁移。SIRT6 activator 12q 诱导细胞凋亡 (Apoptosis) 和细胞周期停滞在 G2 期。SIRT6 activator 12q 显示出抗癌活性。
-
GC69884
Shepherdin (79-87) (TFA)
Shepherdin (79-87) TFA 是 Shepherdin 的 79 至 87 氨基酸片段。Shepherdin 是一种 Hsp90-Survivin 复合物的拟肽拮抗剂。具有抗肿瘤活性。
-
GC69841
Rubropunctatin
Rubropunctatin 是一种从红曲霉发酵米(红霉米)提取物中分离出来的橙色的氮杂酮类色素。 Rubropunctatin 具有抗炎,免疫抑制和抗氧化作用,还具有抗肿瘤活性。
-
GC69801
Ragifilimab
INCAGN-1876
Ragifilimab (INCAGN-1876) 是一种靶向糖皮质激素诱导的 TNFR 相关蛋白 (GITR) 的激动剂单克隆抗体。Ragifilimab 可用于晚期或转移性实体瘤研究。 -
GC69795
(Rac)-BIO8898
(Rac)-BIO8898 是一种 CD40-CD154 共刺激相互作用抑制剂。(Rac)-BIO8898 抑制 CD154 与 CD40-Ig 结合,IC50 为 25 μM。
-
GC69705
Physalin A
Physalin A 是一种从 Physalis alkekengi var franchetii 中分离出来的 withanolide。 Physalin A 诱导细胞凋亡 (apoptosis) 与 caspase-3 和 caspase-8 表达上调相关的。Physalin A 诱导自噬,发现可拮抗 HT1080 细胞的凋亡。Physalin A具有研究癌症疾病的潜力。
-
GC69677
MAX-10181
PD-1/PD-L1-IN-30
MAX-10181 (PD-1/PD-L1-IN-30) 是一种 PD-1/PD-L1 结合抑制剂,IC50 值为 0.018 μM。MAX-10181 可用于癌症及其他相关疾病的研究。 -
GC69676
PD-1/PD-L1-IN-29
PD-1/PD-L1-IN-29(S4-1)是一种有效的 PD-1/PD-L1 抑制剂,其 IC50 值为 6.1 nM。 PD-1/PD-L1-IN-29 可以结合 PD-L1 并破坏 PD -1/PD-L1 相互作用,诱导 PD-L1 二聚化和内化,改善其对内质网的定位,促进 PD-L1 进入内质网。 PD-1/PD-L1-IN-29 具有抗癌活性。
-
GC69675
PD1-PDL1-IN 1 TFA
PD1-PDL1-IN 1 TFA (compound 16) 是有效的程序性细胞死亡 1 (PD-1) 抑制剂。PD1-PDL1-IN 1 TFA 可用作免疫调节剂。